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adequate anticonvulsant treatment should raise the possibility of
pseudostatus epilepticus.
The correct diagnosis was not made in these five patients for
several reasons. Four patients had been diagnosed incorrectly as
probable or definite epilepsy. These diagnoses prejudiced the true
diagnosis when they were admitted. Lack of familiarity with real
seizures contributed since all patients clearly had non-organic
seizures when witnessed by medical staff. None of the patients had
bitten their tongue or been incontinent despite frequent apparent
grand-mal seizures. Most often the so-called seizures consisted of
opisthotonos with alternate flapping of the limbs and twisting of the
head from side to side. Patients responded to pain or commands
during the seizures and there was no colour change. The sequence
of events was identical in every patient. An isolated seizure initially
led to admission to hospital. Further seizures subsequently
occurred on the ward and were treated with diazepam. Seizures
then became increasingly frequent despite increasing doses of
anticonvulsant drugs, culminating in what seemed to be status
epilepticus. None of the patients were in status epilepticus on
admission. Electroencephalographic changes of minor abnormality
were sometimes interpreted as supporting a diagnosis of epilepsy.
Lack of availability of continuous monitoring made diagnosis
difficult but in no patient was pseudoseizure suspected. Two of the
five patients had psychiatric problems and one had a clear emotional
precipitant of the pseudostatus epilepticus. By the time of transfer to
the centre all patients were severely sedated by their medication and
one had previously been in intensive care because of respiratory
depression due to chlormethiazole.
It is thus unwise to diagnose epilepsy if in doubt since once the
label is acquired it is difficult to lose. A trial of anticonvulsant
treatment is rarely useful in establishing the diagnosis of epilepsy
and can lead to unnecessary long-term treatment, as has happened
in two of our patients. Increasingly frequent serial seizures after
admission despite adequate anticonvulsant treatment should raise
the possiblity of pseudostatus epilepticus.
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BRAIN MUSCARINIC RECEPTORS IN ALZHEIMER’S
AND PARKINSON’S DISEASES
SIR,-Dementia without substantial Alzheimer-type changes in
the cerebral cortex is sometimes seen in patients with Parkinson’s
disease.’ Subcortico-cortical cholinergic alterations are features of
both Alzheimer’s disease (AD) and Parkinson’s disease (PD).2,3
Neuronal loss in the nucleus basalis of Meynert is observedn4 and
reductions in cortical choline acetyltransferase (CAT) activity
correlate with the degree of dementia in both diseases.1,5,6 The status
of muscarinic cholinergic receptors is less clear. We have looked at
CAT activity and muscarinic receptor binding in the temporal
cortex (Brodman area 38) and hippocampus in neuropathologically
confirmed AD and PD.
Brain was obtained at necropsy from nine patients with AD and
from nine matched controls with no evidence of neurological or
psychiatric diseases and from nine patients with PD (four with
dementia) and nine matched controls. The demented patients had
profound progressive disturbances in memory and cognitive
impairment. The parkinsonian patients had been on levodopa at the
time of death and two had also received anticholinergic medication.
Neither the patients with AD nor the controls had received any drug
known to affect the central nervous system. Using membrane
homogenates we did saturation analyses for total muscarinic
receptors with [3H]-quinuclidinylbenzilate (QNB) and for type 1
(M-1) receptors with [3H]-pirenzepine. Non-specific binding
was defined by atropine. Protein concentrations and enzyme
activities were measured by standard techniques (details from
K. W. L.).
MEAN (SEM) MAXIMAL RECEPTOR BINDING IN CORTEX AND
HIPPOCAMPUS
Wilcoxon’s rank-sum test: *p < 0 05.
CAT activity in nmol/h/mg protein; QNB and pirenzepine binding as B in &nol/mg
protem.
CAT activity was much reduced in both cortex and hippocampus
in AD and in PD (table). Muscarinic receptors were differently
affected in the two diseases. Patients with AD showed no change in
temporal cortex concentrations of total muscarinic receptors and
M-1 receptors; there was reduced [3H]-QNB binding and
unchanged [3H]-pirenzepine binding in the hippocampus. By
contrast, demented and non-demented patients with PD had
increased concentrations of both the total muscarinic receptors and
M-1 receptors in the cortex and no alterations in hippocampal
receptors. Altered K values were not observed.
Different alterations of muscarinic receptors in AD and PD may
reflect fundamental differences in the pathophysiological process
underlying dementia in these diseases. Increased concentrations of
cortical muscarinic receptors may represent a compensatory
mechanism which can maintain normal cognitive function in PD
during the early stages of altered cholinergic transmission.7 Despite
extensive CAT loss in AD and PD, muscarinic receptor alterations
are far less striking and retain the potential for pharmacological
replacement therapy of the cholinergic deficit.
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